Cellular KRAS(G12C) Protein Degradation Assay

Cellular KRAS(G12C) Protein Degradation in PROTAC LC-2 Treated MIA PaCa-2 Cells by Western Blot

Target Overview



HGNC Symbol




Cell Line

MIA PaCa-2 cells from ATCC

Assay Properties

Assay Format

Western Blot

Assay Protocol

KRAS(G12C) mutant MIA PaCa-2 pancreatic cancer cells were seeded into the wells of 12-well plates. The cells were treated with reference PROTAC compound LC-2 for 24 hours. The cell lysates were subjected to Western blot analysis. The blot was probed with KRAS antibody and then re-probed with α-Tubulin antibody. The membrane was scanned by LI-COR Odyssey Fc Imaging System. The specific bands of interest were quantified by LI-COR Image Studio Lite software. KRAS(G12C) expression bar graph was plotted using the GraphPad Prism program.


LI-COR Odyssey Fc Imaging System

Reference Compound

Screening Location

Malvern, PA, USA

Further information

More information can be found on our website Protein Degradation Assay – PROTAC Screening

Western blot for detection of KRAS(G12C) degradation in PROTAC LC-2 treated MIA PaCa-2 cells

Western blot for detection of KRAS(G12C) degradation

Western blot quantification for detection of PROTAC LC-2 induced KRAS(G12C) degradation

Western blot quantification